This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
CVD is especially prevalent in the Medicare-aged population, affecting more than 75 percent of those aged 60-79 and more than 90 percent of those aged 80 and over. About the Study The study evaluated engagement and clinical outcomes among age 65+ participants of an mHealth app-based CV risk self-management program.
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. The company recently announced it has received CMS approval for Medicare coverage during the DRAIN-HF pivotal trial.
With this new funding, Cleerly will continue to scale its commercial growth and clinical evidence generation, helping health care professionals improve outcomes for patients across the coronary care pathway. We’re proud to be a part of Cleerly’s journey. This is what good software can do in the world!"
v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
milla1cf Tue, 04/23/2024 - 16:03 April 23, 2024 — CDL Nuclear Technologies , a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. CDL provides this service in compliance with all healthcare regulations. webflow.io
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , said Peter Altman , PhD., BioCardia’s President and Chief Executive Officer. “To
1 To qualify for a Breakthrough Device Designation, a device technology must address an unmet need and show that it has the potential to provide for more effective treatment of life-threatening diseases or irreversibly debilitating conditions. CLTI is associated with high rates of amputation and mortality as well as high care costs.1
This launch coincides with the receipt of pass-through status by the CMS, effectiveApril 1, securing a drug-specific Healthcare Common Procedure Coding System (HCPCS) billing code and coverage for traditional Medicare beneficiaries.
Removing these barriers would allow surgeons, physicians, hospitals, health systems, and others to conduct longitudinal analyses and gain new insights into long-term outcomes for patients undergoing procedures such as coronary artery bypass grafting (CABG)—the most common operation performed by cardiac surgeons.
Consequently, Philips is well positioned to support CVI treatment by offering a robust portfolio of medical technology that includes both intravascular ultrasound and a differentiated venous stenting system.” Ultimately, the new device promises to enable excellent clinical outcomes and drive significant quality of life improvements.”
To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. Technology tools are becoming more sophisticated, bidirectional and disease-specific, and are being designed with home care in mind.
Established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) , the MIPS Program is pivotal in determining Medicare payment adjustments for healthcare practices. What is MIPS?
Introduction:This study evaluates the outcomes of a survivor-centric, navigator-driven, technology-enabled platform supporting survivors (SS) and care partners(CP) in post-stroke recovery. This mixed methods study utilizes focus group feedback, survey, app usage and patient-reported outcomes data.
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. We thank the FDA for its speedy review and approval of the important follow-on Phase III trial.
I learned about the complexities of health insurance – and after several years, I transitioned to the Medicare & Retirement Clinical value team where we worked to reduce the cost of United’s Medicare Advantage plans. Technology in healthcare is a double-edged sword.
The development has urged us to integrate the latest Artificial Intelligence with the healthcare system, including Cardiac Medicare. By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patient care. What is Artificial Intelligence? For instance: 1.
With more than 500 peer-reviewed publications, the HeartFlow FFR CT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes. 3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives.
In late 2023, CMS released the 2024 Medicare Physician Fee Schedule (MPFS) Final Rule, ushering in key policy changes for the Quality Payment Program (QPP). Report 6 measures, including one Outcome or other High Priority measure for 12 months on at least 70% of eligible encounters to receive a score based on 2023 National Benchmarks.
RPM solutions are improving healthcare outcomes and helping patients lead healthier lives. With effective management and use, RPM can provide clinicians with the tools to improve patient outcomes and deliver better quality care. What is Cardiac Remote Patient Monitoring Software ?
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) has granted Category B approval for the investigational device exemption (IDE) study, ensuring Medicare coverage for the device, related and routine items, and services for the ELITE-BTK trial. Commenting on the announcements, Christopher M.
13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. 5 Bhatt, D.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content